# Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

> **NCT01216683** · PHASE2 · COMPLETED · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 289 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** Bendamustin
- **DRUG:** bortezomib
- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT01216683
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-09
- **Primary completion:** 2019-12-02
- **Final completion:** 2019-12-02
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2023-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01216683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01216683, "Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01216683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*